2020
Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis
Saito M, Mansoor R, Kennon K, Anvikar AR, Ashley EA, Chandramohan D, Cohee LM, D'Alessandro U, Genton B, Gilder ME, Juma E, Kalilani-Phiri L, Kuepfer I, Laufer MK, Lwin KM, Meshnick SR, Mosha D, Mwapasa V, Mwebaza N, Nambozi M, Ndiaye JA, Nosten F, Nyunt M, Ogutu B, Parikh S, Paw MK, Phyo AP, Pimanpanarak M, Piola P, Rijken MJ, Sriprawat K, Tagbor HK, Tarning J, Tinto H, Valéa I, Valecha N, White NJ, Wiladphaingern J, Stepniewska K, McGready R, Guérin PJ. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases 2020, 20: 943-952. PMID: 32530424, PMCID: PMC7391007, DOI: 10.1016/s1473-3099(20)30064-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyIndividual patient dataQuinine-based treatmentsUncomplicated falciparum malariaPregnant womenArtemether-lumefantrineFalciparum malariaTreatment failureOne-stage individual patient dataSystematic reviewPatient dataObservational cohort studyAcute adverse eventsClinical Trials RegistryGametocyte carriageQuinine monotherapyAsexual parasitaemiaFever clearanceAdverse eventsCohort studyParasite clearanceTreatment guidelinesTrials RegistryCombination therapyRisk factors
2016
Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study
Sambol NC, Tappero JW, Arinaitwe E, Parikh S. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. PLOS ONE 2016, 11: e0154623. PMID: 27182702, PMCID: PMC4868321, DOI: 10.1371/journal.pone.0154623.Peer-Reviewed Original ResearchConceptsPopulation pharmacokinetic modelWeekly dosingUncomplicated Plasmodium falciparum malariaSteady-state trough concentrationsPharmacokinetic modelYoung childrenStandard therapeutic dosesYoung Ugandan childrenFirst-line therapyPlasmodium falciparum malariaFuture trial designPeak concentrationPlasma concentration-time profilesPercent of childrenConcentration-time profilesPiperaquine concentrationsMalaria chemopreventionBreakthrough infectionsMonthly administrationTrough concentrationsAcute treatmentFalciparum malariaLoading doseChemopreventive regimensInitial dosing
2015
Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria
Sambol N, Yan L, Creek D, McCormack S, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero J, Lindegardh N, Tarning J, Nosten F, Aweeka F, Parikh S. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria. Clinical Pharmacology & Therapeutics 2015, 98: 87-95. PMID: 25732044, PMCID: PMC5088713, DOI: 10.1002/cpt.104.Peer-Reviewed Original ResearchConceptsUncomplicated malariaPopulation pharmacokineticsYoung Ugandan childrenWeight-based dosingChildren 6 monthsAge-specific guidelinesClearance/bioavailabilityFirst-order absorptionDihydroartemisinin-PiperaquinePiperaquine exposureMalaria episodesProspective trialOral dosesUgandan childrenPlasma concentrationsThree-compartment modelDay 7High dosesAge groupsEarly childhoodPiperaquineDosingPharmacokineticsMalariaPhysiological changes
2013
Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants
Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants. The Journal Of Infectious Diseases 2013, 207: 1646-1654. PMID: 23447696, PMCID: PMC4318925, DOI: 10.1093/infdis/jit078.Peer-Reviewed Original ResearchConceptsPiperaquine concentrationsRecurrent malariaDay 7TMP-SMXDihydroartemisinin-piperaquine treatmentPK/PD studiesTMP-SMX prophylaxisTrimethoprim-sulfamethoxazole prophylaxisTime of presentationPK/PD dataYears of ageYoung childrenPiperaquine exposureUgandan infantsUncomplicated malariaMalaria treatmentPharmacodynamic dataDP useDay 28PD studiesMalariaDay 63Strong associationPQ concentrationProphylaxis
2012
Population Pharmacokinetics and Pharmacodynamics of Piperaquine in Children With Uncomplicated Falciparum Malaria
Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo J, Lindegardh N. Population Pharmacokinetics and Pharmacodynamics of Piperaquine in Children With Uncomplicated Falciparum Malaria. Clinical Pharmacology & Therapeutics 2012, 91: 497-505. PMID: 22258469, PMCID: PMC3736305, DOI: 10.1038/clpt.2011.254.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaPopulation pharmacokineticsThree-compartment distribution modelNonlinear mixed-effects modelingRecurrent malaria infectionsTotal piperaquine exposureArtemisinin combination treatmentWeight-normalized dosePlasma concentration-time profilesYoung childrenMixed-effects modelingConcentration-time profilesPiperaquine concentrationsPiperaquine exposureDose regimenMalaria infectionPlasma concentrationsPharmacodynamic propertiesCombination treatmentBody weightPiperaquineSignificant covariatesOlder childrenMalaria